N4 Pharma Plc (AIM:N4P)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.4700
-0.0050 (-1.05%)
Feb 13, 2026, 3:08 PM GMT
Market Cap3.95M +43.1%
Revenue (ttm)7.07K +20.6%
Net Income-1.10M
EPS-0.00
Shares Out832.28M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume601,389
Average Volume299,158
Open0.4500
Previous Close0.4750
Day's Range0.4500 - 0.5000
52-Week Range0.3500 - 1.0000
Beta0.17
RSI5.41
Earnings DateMar 9, 2026

About N4 Pharma

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-cl... [Read more]

Sector Healthcare
Founded 1979
Employees 4
Stock Exchange London Stock Exchange AIM
Ticker Symbol N4P
Full Company Profile

Financial Performance

In 2024, N4 Pharma's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.

Financial Statements